Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label BMS-986094-INX 189 halted. Show all posts
Showing posts with label BMS-986094-INX 189 halted. Show all posts
Thursday, January 24, 2013

Bristol Reaches $80 Million Deal to Settle Hepatitis C Claims

›
Report: Bristol-Myers Squibb settles hepatitis C drug claims for $80 million (Ref: NASDAQ, The Wall Street Journal) January 24th, 2013 ...
Tuesday, January 15, 2013

Bristol-Myers to Hold Talks On Settling Claims of Hepatitis C Patients

›
Bristol-Myers to Hold Talks On Settling Claims of Hepatitis C Patients By JONATHAN D. ROCKOFF Bristol-Myers Corp. BMY +0.26% is sch...
Monday, October 22, 2012

Setbacks in HCV Drug Development Highlight Uncertainties in Treat or Wait Decisions

›
Setbacks in HCV Drug Development Highlight Uncertainties in Treat or Wait Decisions Source- Clinical Care Options Graham R. Foster FRC...
Wednesday, October 3, 2012

The Top Phase III Disasters of 2012 - BMS-094 - Bristol-Myers

›
Topics: Clinical Trials   The Top Phase III Disasters of 2012 October 3, 2012 | By John Carroll Excerpt: Every year we see a good nu...
Friday, September 21, 2012

Idenix Pharma: Guilty By Association

›
Idenix Pharma: Guilty By Association   By Nathan Sadeghi-Nejad   Excerpt: IDX-184 has had no safety issues to date. Nonetheless, ...
Monday, September 17, 2012

Casualties of an R&D war? Hep C trial patients accuse Bristol-Myers of recklessness

›
Casualties of an R&D war? Hep C trial patients accuse Bristol-Myers of recklessness September 17, 2012 | By John Carroll   Bri...
Sunday, September 16, 2012

BMS-986094 :Trial of hepatitis C drug has deadly outcome

›
Trial of hepatitis C drug has deadly outcome for area man Test of experimental hepatitis C remedy turns fatal for area patient, shows risk...
Friday, August 24, 2012

BMS halts the development of BMS-986094 due to patient death

›
Bristol-Myers halts mid-stage study of promising hepatitis C drug Published: Thursday, August 23, 2012, 7:25 PM Updated: Thursday, Augus...